A study by researchers at the University of California, Berkeley, found that patients who have access to both the prices charged by a testing laboratory as well as reference pricing, they choose lower-cost laboratories, resulting in overall cost savings.
The monoclonal antibody daratumumab (Darzalex) has been granted breakthrough designation, the second for this drug, for use in combination with either lenalidomide and dexamethasone or bortezomib and dexamethasone, for patients with multiple myeloma who have received at least 1 prior therapy.
A collaborative pilot that includes the California Department of Public Health, is studying whether near—real-time reporting of cancer diagnoses by pathologists will permit providers to make more informed and timely treatment decisions.
According to a news report in Nature, scientists at Sichuan University’s West China Hospital are on track to initiate a clinical trial that will administer CRISPR-Cas9—edited immune cells in patients diagnosed with lung cancer.
A letter published in The New England Journal of Medicine provides narrative of a clinical interference that has been documented with the much hailed multiple myeloma drug daratumumab.
A proof-of-concept study in ovarian cancer shows advantage of using liquid biopsy for the earlier detection of disease relapse.
The US Department of Justice (DOJ) has filed an antitrust lawsuit to prevent planned megamergers in the health insurance industry.
While most adolescent survivors of childhood cancer have a good grip on their emotional well being, some frequently present with a combination of behavioral, emotional, and social symptoms, a new study published in the Journal of Clinical Oncology has concluded
On an earnings call yesterday, Novartis announced that the FDA has sent a complete response letter for their product pegfilgrastim, biosimilar to Neulesta.
During a health policy session at the annual meeting of the American Society of Clinical Oncology, Steven J. Katz, MD, MPH, discussed the Oncotype DX Breast Cancer Assay, and it's impact on recommendations for chemotherapy in early-stage breast cancer.
A study presented at the annual meeting of the American Society of Clinical Oncology by a group from Israel that evaluated the price trend of 30 anticancer agents following their launch, found that prices may increase by as much as 44% even after adjusting for inflation.
A long-term follow up study among Dutch women who underwent in-vitro fertilization (IVF) treatment in the Netherlands has failed to find an association between the treatment and an increased risk of breast cancer.
Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA mismatch repair.
According to the study published in Cancer, adjuvant chemotherapy in patients with early stage colon cancer results in clinically relevant improvement in overall survival.
Drug prices have developed into the fastest growing segment of healthcare costs and are a significant burden on the patient's wallet, in addition to the cost of healthcare services. An Education Session at the annual meeting of the American Society of Clinical Oncology discussed potential solutions to ease this problem.
A poster presented at the annual meeting of the American Society of Clinical Oncology evaluated the cost per median month of survival for daratumumab and other novel treatments for multiple myeloma.
Despite their known risk, only half the women over 85 years of age in a cohort being evaluated had their baseline bone density tested prior to initiating treatment.
A session at the annual meeting of the American Society of Clinical Oncology (ASCO) provided an overview of the ASCO value framework and it's quality improvement program, the Quality Oncology Practice Initiative.
On the first day of the annual meeting of the American Society of Clinical Oncology, healthcare experts from the United States, Canada, and the United Kingdom, compared and contrasted the care models that are widely adopted in each nation.
Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin gene were found responsible for lack of response to interferon gamma.
During a clinical session at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarkers for the new immunotherapies.
At the annual meeting of the American Society of Clinical Oncology, results were presented from a phase 1/2 trial in which patients with relapsed or refractory CD19+ B-cell malignancies were treated with CD19 CAR-T cells.
A study has found that an 8-gene signature score, combined with nodal status and tumor size, obtained from the EndoPredict breast cancer test might be more accurate at predicting the recurrence of breast cancer, compared with the recurrence score of Oncotype DX.
The ROCKET trial was halted last week following news of 3 patient deaths due to cerebral edema.
As immunotherapy-particularly the checkpoint inhibitors-continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes.
At the annual meeting of the American Society of Clinical Oncology, held June 3-7, 2016, phase 1 data from the CheckMate 143 trial was presented during a poster session.
Promotional advertising by cancer centers has seen a dramatic spike in recent years, with 890 cancer centers spending $173 million for advertising in 2014.
The National Cancer Institute (NCI) estimates that the aging US population will contribute to a substantial increase in the number of older cancer survivors over the next 25 years.
According to a study conducted in the United Kingdom, statins can reduce the risk of dying from breast, prostate, lung, and bowel cancer.
The FDA has asked Juno Therapeutics to halt the phase 2 clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, the ROCKET trial.